Cytek Biosciences Reports Q1 2025 Revenue Drop of 7.6% and Adjusted EBITDA Loss of $5.5 Million

Reuters
09 May
Cytek Biosciences Reports Q1 2025 Revenue Drop of 7.6% and Adjusted EBITDA Loss of $5.5 Million

Cytek Biosciences Inc., a leading cell analysis solutions company, reported its financial results for the first quarter of 2025. Total revenue for the quarter was $41.5 million, marking a 7.6% decrease compared to the first quarter of 2024. This decline in revenue was attributed to a slowdown in product sales in the US and EMEA regions, although it was partially offset by strong performance in the APAC region and robust service revenue worldwide. The company recorded a gross profit of $20.2 million for the first quarter of 2025, reflecting a 12% decrease from the previous year. Excluding investment income, Cytek reported an Adjusted EBITDA loss of $5.5 million, compared to a loss of $2.6 million in the first quarter of 2024. As of March 31, 2025, Cytek's cash and marketable securities stood at $265.6 million, down from $277.9 million as of December 31, 2024. This decrease of $12.3 million occurred despite a cash expenditure of $10.6 million for the repurchase of Cytek shares during the first quarter. In its 2025 outlook, Cytek revised its full-year revenue guidance to a range between $196 million and $210 million, indicating potential growth of -2% to 5% over the full year 2024, assuming no change in currency exchange rates. Significant operational updates include the expansion to a total installed base of 3,149 Cytek instruments, the commencement of operations in Singapore to enhance manufacturing capacity and global supply flexibility, and the launch of the Cytek Muse® Micro instrument, aimed at simplifying flow cytometry with enhanced precision and versatility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-115965), on May 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10